New cancer clinical trial: Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer

Published on: March 19, 2018 at 12:00PM
Condition:   Colorectal Cancer Metastatic
Intervention:   Drug: Galunisertib
Sponsors:   The Netherlands Cancer Institute;   Vall d'Hebron Institute of Oncology;   Agendia;   European Organisation for Research and Treatment of Cancer - EORTC;   Azienda Ospedaliera Niguarda Cà Granda;   Fundación para la Investigación del Hospital Clínico de Valencia;   University of Campania "Luigi Vanvitelli";   University of Turin, Italy;   Eli Lilly and Company;   Catalan Institute of Health;   Universitaire Ziekenhuizen Leuven
Not yet recruiting
http://ift.tt/2u7zA7E